Evidence map›Paper›PMID 36029009›Full record

ArticleAntiviral therapy2022

Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand.

European Pregnancy And Paediatric Infections Cohort Collaboration Eppicc, Alex Lyons, Lindsay Thompson, Elizabeth Chappell, Luminita Ene, Luisa Galli, Tessa Goetghebuer, Gonzague Jourdain, Antoni Noguera-Julian, Christian R Kahlert and 18 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 19 institutions in 13 countries.

European Pregnancy And Paediatric Infections Cohort Collaboration Eppicc
Alex LyonsMRC Clinical Trials Unit at UCL, 4919University College London, London, UK.
Lindsay ThompsonMRC Clinical Trials Unit at UCL, 4919University College London, London, UK.
Elizabeth ChappellMRC Clinical Trials Unit at UCL, 4919University College London, London, UK.
Luminita EneClinical Department of Infectious Diseases (HIV Department), Dr. Victor Babeș Hospital for Infectious and Tropical Diseases, Bucharest, Romania.
Luisa GalliInfectious Disease Unit, Meyer Children's Hospital, Department of Health Sciences, University of Florence, Florence, Italy.
Tessa GoetghebuerHopital St Pierre, Brussels, Belgium.
Gonzague JourdainInstitut de recherche pour le développement (IRD)-PHPT, Marseille, France.
Antoni Noguera-JulianInfectious Diseases and Systemic Inflammatory Response in Pediatrics, Infectious Diseases Unit, Department of Pediatrics, Sant Joan de Déu Hospital Research Foundation, Barcelona, Spain.
Christian R KahlertInfectious Diseases and Hospital Epidemiology, Children's Hospital of Eastern Switzerland and Cantonal Hospital, St Gallen, Switzerland.
Christoph KönigsDepartment for Children and Adolescents, Division for Stem Cell Transplantation and Immunology, University Hospital Frankfurt/Main, Frankfurt, Germany.
Pope KosalaraksaDepartment of Pediatrics, Khon Kaen University, Khon Kaen, Thailand.
Pagakrong LumbiganonDepartment of Pediatrics, Khon Kaen University, Khon Kaen, Thailand.
Magdalena MarczyńskaHospital of Infectious Diseases, 37803Medical University of Warsaw, Warsaw, Poland.
Laura MarquesCentro Hospitalar e Universitário do Porto, Porto, Portugal.
Marissa NavarroHospital General Universitario "Gregorio Marañón", Madrid, Spain.
Lars NaverKarolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Liubov OkhonskaiaFederal Budgetary Institution "Republican Clinical Infectious Hospital" of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation.
Filipa PrataHospital de Santa Maria/CHULN, Lisbon, Portugal.
Thanyawee PuthanakitDepartment of Pediatrics, Faculty of Medicine, 26683Chulalongkorn University and HIVNAT, Thai Red Cross AIDS Research Center, Bangkok, Thailand.
Jose T RamosDepartamento de Salud Pública y Materno-infantil, Universidad Complutense, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Anna SamarinaThe City HIV Centre, St Petersburg City AIDS Center, St Petersburg, Russian Federation.
Claire ThorneUniversity College London Great Ormond Street Institute of Child Health, London, UK.
Evgeny VoroninFederal Budgetary Institution "Republican Clinical Infectious Hospital" of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation.
Anna TurkovaMRC Clinical Trials Unit at UCL, 4919University College London, London, UK.
Carlo Giaquinto561043Paediatric European Network for the Treatment of AIDS (Penta), Padova, Italy.
Ali JuddMRC Clinical Trials Unit at UCL, 4919University College London, London, UK.
Intira J CollinsMRC Clinical Trials Unit at UCL, 4919University College London, London, UK.ORCID 0000-0003-2132-6037
MRC Clinical Trials Unit at UCL · GBGreat Ormond Street Hospital · GBKhon Kaen University · THMinistry of Health of the Russian Federation · RUCentre Hospitalier Universitaire de Saint-Pierre · BECentro Hospitalar do Porto · PTChulalongkorn University · THGoethe University Frankfurt · DEHospital de Santa Maria · PTInstitut de Recherche pour le Développement · FRInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ESKarolinska University Hospital · SEMedical University of Warsaw · PLMeyer Children's Hospital · ITPENTA Foundation · ITSant Joan de Déu Research Foundation · ESSpitalul Clinic Dr. Victor Babes · ROUniversidad Complutense de Madrid · ESUniversity of St.Gallen · CH

Funding

Medical Research Council MC_U122886353Medical Research Council MC_UU_00004/03Medical Research Council MC_UU_12023/17Medical Research Council MC_UU_12023/26
6 · The paper itself

Abstract

backgroundEtravirine (ETR) is approved as a component of second or third-line antiretroviral treatment (ART) for children living with HIV. We assessed the outcomes of ETR-based ART in children in routine care in Europe and Thailand.

methodsData on children aged <18 years at ETR start were pooled from 17 observational cohorts. Characteristics at ETR start, immunological and virological outcomes at 12 months, discontinuations, adverse events (AEs) and serious adverse events (SAEs) were described. Follow-up was censored at ETR discontinuation, death or last visit.

results177 children ever received ETR. At ETR start, median [IQR] age was 15 [12,16] years, CD4 count 480 [287, 713] cells/mm

conclusionChildren receiving ETR were predominantly highly treatment-experienced, over two-thirds were virally suppressed at 12 months.

Indexed as

Anti-HIV AgentsHIV InfectionsPyridazinesAdolescentAnti-Retroviral AgentsCD4 Lymphocyte CountChildHumansNitrilesPyrimidinesThailandTreatment OutcomeViral LoadAnti-HIV AgentsAnti-Retroviral AgentsetravirineNitrilesPyridazinesPyrimidines

Identifiers

PMID36029009
PMCPMC7614682
OpenAlexW4293506691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.